Mankind Pharma Reports Highest Quarterly Sales Amid Mixed Financial Performance in June 2025
Mankind Pharma has announced its financial results for the quarter ending June 2025, reporting net sales of Rs 3,570.35 crore, the highest in five quarters. However, profit after tax and profit before tax both declined compared to previous quarters, alongside a notable increase in interest expenses.
Mankind Pharma, a prominent player in the Pharmaceuticals & Biotechnology sector, has released its financial results for the quarter ending June 2025. The company reported net sales of Rs 3,570.35 crore, marking the highest quarterly sales in the last five quarters, indicating a positive near-term sales trend.However, the financial results also highlight some challenges. The company's profit after tax (PAT) for the quarter stood at Rs 438.32 crore, reflecting a decline compared to the average PAT of the previous four quarters. Similarly, profit before tax (PBT), excluding other income, was recorded at Rs 460.61 crore, also showing a decrease relative to past performance. Additionally, interest expenses have risen significantly, with the latest six-month figure reaching Rs 361.19 crore, which suggests an increase in borrowings.
In light of these developments, Mankind Pharma has experienced an adjustment in its evaluation, with its score improving to -4 from -12 over the past three months. This revision reflects the mixed performance observed in the latest financial results.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
